Prevalence of the Use of Aspirin and Statins for Preventing Cardiovascular Events in the Colombian Population with Type 2 Diabetes Mellitus: Comparison of 2008 and 2018

Abstract

Background

Type 2 diabetes mellitus (T2DM) greatly increases cardiovascular risk. Primary and secondary cardiovascular prevention lead to lower cardiovascular events, improved quality of life and lower costs related to complications.

Objective

To estimate the proportion of patients with T2DM undergoing drug therapy for cardiovascular prevention (aspirin and statins) in Colombia and to describe the change in patterns of use between 2008 and 2018.

Methods

This was a cross-sectional study comparing prescriptions for aspirin and statins in 2008 and in 2018 in outpatients diagnosed with T2DM. Records were obtained from a national drug claim database. The proportion of use of cardiovascular prevention drugs and antidiabetic drugs, medications for comorbidities and sociodemographic variables were analyzed for both periods.

Results

In total, 26 742 patients in 2008 and 188 321 in 2018 with a diagnosis of T2DM treated with antidiabetic drugs were identified, among whom 57.5% and 44.2% received aspirin and 44.9% and 60.2% received statins, respectively. The use of high-intensity statins increased from 1.1% in 2008 to 95.2% in 2018. The probabilities of receiving drugs in 2008 and in 2018 were higher for men (OR: 1.12, 95% CI: 1.06-1.17 and OR: 1.26, 95% CI: 1.23-1.28, respectively), for those persons over 75 years of age (OR: 6.5, 95% CI: 5.3-7.9 and OR: 5.8, 95% CI: 5.4-6.2) and for those who also received clopidogrel (OR: 5.8, 95% CI: 4.4-7.6 and OR: 2.2, 95% CI: 2.1-2.4).

Conclusions

The use of high-intensity statins in patients with T2DM has increased significantly in the last decade, which should reduce cardiovascular events, morbidity and mortality.

Keywords

Type 2 diabetes mellitus cardiovascular diseases aspirin hydroxymethylglutaryl-CoA reductase inhibitors hypolipidemic agents pharmacoepidemiology

Introduction

Chronic noncommunicable diseases are currently considered an epidemic.^1-3 Among the leading causes of death globally are pathologies of cardiovascular origin, which are strongly linked to type 2 diabetes mellitus (T2DM), dyslipidemia, and high blood pressure (HBP). According to various reports, cardiovascular disease is the leading cause of death worldwide, including Latin America and Colombia.^2-4

T2DM greatly increases cardiovascular risk.^5,6 Globally, the population with T2DM numbers 476 million, and when standardized by age, the global prevalence of T2DM is 5.8%. In Colombia, the estimated prevalence is between 4% and 8%.⁷ In the absence of adequate control and preventive measures, the pathology of T2DM entails a higher incidence of acute myocardial infarction and other cardiovascular conditions.⁵ Recommendations for cardiovascular prevention in this population include healthy lifestyle habits and pharmacological therapies for controlling blood sugar, blood pressure, dyslipidemia, and platelet aggregation. These last 2 therapies have also been used in primary cardiovascular prevention.^8,9

Primary and secondary cardiovascular prevention result in decreased cardiovascular events, improved quality of life and lower costs related to complications.¹⁰ However, despite guidelines and evidence supporting the efficacy and safety of lipid-lowering therapies, between 4% and 79% of patients with high cardiovascular risk and diabetes adhere to treatment, with a smaller percentage achieving glycemic control and serum cholesterol treatment goals.^9,11-13 In the United States, less than half of patients receive the recommended therapies (aspirin, statins, blood pressure, and diabetes medications) for cardiovascular prevention.¹⁴ In Colombia, only 38.6% of high-risk cardiovascular patients achieve cholesterol low density lipoprotein (LDL) goals,¹⁵ and 32.2% of patients who routinely receive aspirin have concomitant T2DM.¹⁶

There is no current published data from Colombia regarding the prevalence of use of medications such as aspirin or statins among individuals with T2DM. From a pharmacoepidemiological perspective, understanding the changes in the patterns of medications over time is important for evaluating the national public health interventions. The purpose of this study was to estimate the proportion of people with T2DM receiving drug therapy for cardiovascular prevention (aspirin and statins for this study) in Colombia, to describe the changes from 2008 to 2018 and to identify possible variables associated with the use of these medications.

Methods

Study Design

A cross-sectional study was conducted. Data were obtained from a national drug claim database containing the records of approximately 6.5 million people, which represents 13.5% of the country’s total population. The dispensing information was from 5 different healthcare insurance companies (EPS) of the contributory regime (social health insurance for workers and families), which is present in all regions of Colombia.

The information in its entirety was obtained from the dispensing database of Audifarma SA, which has been used in multiple pharmacoepidemiological studies.^5,15-17

Participants and Setting

The study included all ambulatory patients over 18 years of age, of either sex, diagnosed with and treated for T2DM through the Health System of Colombia at 5 healthcare insurers and who had drug claims registered in the database; a patient was defined as having T2DM if he/she had a registered diagnosis (International Classification of Diseases-ICD10 codes: E110-E149) and received medications for T2DM continuously during the last quarters of 2008 and 2018 (dispensed each month). Exclusion criteria were not considered for this study.

Data Collection

After identification of the included patients, the following variables were determined:

Sociodemographic: age (according to groups: young adult: 18-44 years; middle adult: 45-64 years; older adult: 65-74 years; and elderly: over 75 years),¹⁸ sex and city of residence.

Diabetes control medications: (a) metformin; (b) sulfonylureas; (c) thiazolidinediones; (d) dipeptidyl peptidase 4 (DPP-4) inhibitors; e) glucagon-like peptide-1 (GLP-1) receptor agonists; (f) sodium-glucose cotransporter-2 (SGLT-2) inhibitors; and (g) insulins.

Cardiovascular prevention medications: (a) prescription of any statin (high-intensity statins were categorized as atorvastatin doses ≥ 40 mg/day and rosuvastatin doses ≥ 20 mg/day); (b) antiplatelet drugs: use of aspirin and use of P2Y12 inhibitors.

Other comedications: antihypertensive, antiulcer, antidepressant, antianginal and anticoagulant medications, nonsteroidal anti-inflammatory drugs (NSAIDs), fibrates, levothyroxine, beta 2-adrenergic agonists and inhaled anticholinergics.

Statistical Analysis

A database was created in Microsoft Excel 2016 with the identified variables. The analyses were performed in SPSS v24.0 (IBM, USA). Frequencies and proportions of the categorical variables were established in order to determine the prevalence of medication use for cardiovascular prevention in patients with T2DM. Bivariate analyses were performed to establish possible associations with cardiovascular prevention drug prescriptions (aspirin and statins together) among the included T2DM patients, and the subsequent multivariate analysis was designed to adjust the associated variables (comparing those T2DM patients with prescriptions for these medications to those without prescriptions). P values less than .05 indicated statistical significance.

Bioethical Considerations

The study was approved by the Bioethics Committee of the Universidad Tecnológica de Pereira (Colombia, South America) in the category of “risk-free research” following the principles established by the Declaration of Helsinki. Access to dispensing data was obtained with the permission of Audifarma S.A.

Results

A total of 26 741 participants were identified from the last quarter of 2008, mostly from the Bogotá-Cundinamarca, Central and Caribbean regions, and 188 321 patients with a diagnosis of T2DM and receiving pharmacological treatment were identified from the last quarter of 2018, mainly from the Bogotá-Cundinamarca, Pacific, and Central regions. At both timepoints, there was a slightly more women than men, and the average patient age was lower in 2018 than in 2008. Among comedications, antihypertensives were predominant (mainly angiotensin II receptor blockers [ARB-II] and angiotensin-converting enzyme inhibitor [ACEI]), followed by antiulcer drugs such as proton pump inhibitors. Table 1 provides the sociodemographic characteristics with comedications for the 2 groups of patients.

Table 1.

Sociodemographic Characteristics and Comedications of Patients with Type 2 Diabetes Mellitus in the Last Trimesters of 2008 and 2018.

Sociodemographic characteristics and comedication		Last quarter 2008		Last quarter 2018
Sociodemographic characteristics and comedication		n = 26 741	%	n = 188 231	%
Sex	Female	15 096	56.5	108 789	57.8
Age (years)	Mean/SD^a	69.4/13.6		63.8/13.5
Regions (Colombia)	Amazonia-Orinoquia	43	0.2	640	0.3
	Bogota-Cundinamarca	13 546	50.7	66 879	35.5
	Caribbean	4000	15.0	32 895	17.5
	Central	6155	23.0	40 314	21.4
	West region	1509	5.6	6438	3.4
	Pacific	1488	5.6	41 155	21.9
Comedications
Analgesics	NSAID^b	3798	14.2	16 321	8.7
Antianginal gents	Nitrates	357	1.3	1370	0.7
Anticoagulants	Apixaban	—	—	781	0.4
	Dabigatran	—	—	451	0.2
	LMWFH^c	240	0.9	2393	1.3
	UFH^d	20	0.1	617	0.3
	Rivaroxaban	—	—	1378	0.7
	Warfarin	339	1.3	1250	0.7
Antidepressants	Serotonin uptake inhibitor	1077	4.00	11 335	6.0
	Serotonin and noradrenaline uptake inhibitor	6	0	545	0.3
	Tricyclic	179	0.7	2206	1.2
Antihypertensives		19 838	74.1	135 610	72.0
	ARB-II^e	8418	31.5	97 253	51.6
	β-blockers	5338	20	41 864	22.2
	Alpha-1 antagonist	884	3.3	7418	3.9
	Clonidine	687	2.6	4791	2.5
	Calcium Channel Blockers	7109	26.6	50 353	26.7
	ACEI^f	10 716	40.1	28 054	14.9
Antiulcer	Antacids	1181	4.4	10 288	5.5
	Bismuth subsalicylate	—	—	6	0
	PPI^g	7662	28.7	48 169	25.6
	Ranitidine	621	2.3	6912	3.7
	Sucralfate	182	0.7	2743	1.5
Levothyroxine	Levothyroxine	—	—	458	0.2
Bronchodilators	Anticholinergic	1027	3.8	7845	4.2
Bronchodilators	β2 adrenergic agonist	1095	4.1	7188	3.8
Fibrates		4048	15.1	12 272	6.5

Standard deviation. ^bNonsteroidal anti-inflammatory drugs. ^cLow-molecular-weight fragment of heparin. ^dUnfractionated heparin. ^eAngiotensin II receptor blockers. ^fAngiotensin-converting enzyme inhibitor. ^gProton Pump Inhibitors.

Antidiabetic Drugs

The most-prescribed antidiabetic drugs for 2008 were metformin (n: 20 545; 76.8%), sulfonylureas (n: 12 795; 47.5%) and insulins (n: 9065; 34.0%) and for of 2018 were metformin (n: 167 415; 87.7%), insulins (n: 79 857; 42.4%) and DPP-4 inhibitors (n: 32 596; 17.2%). Prescription data for antidiabetic drugs are provided in Table 2. A change in the pattern of use of human insulins was observed: the share of patients receiving these drugs decreased from 31.5% in 2008 to 3.5% in 2018, while the use of insulin analogs increased from 2.5% in 2008 to 38.9% in 2018. Table 3 provides the patterns of use of antidiabetic drugs by group and in combinations.

Table 2.

Prescription of Antidiabetic Drugs for Patients with Type 2 Diabetes Mellitus in the Last Trimesters of 2008 and 2018.

Antidiabetic drugs	Pharmaceutical form	Last quarter 2008		Last quarter 2018
Antidiabetic drugs	Pharmaceutical form	n = 26 741	%	n = 188 231	%
Biguanides
Metformin	500 mg	2	0	14 388	7.6
	850 mg	20 533	76.8	119 781	63.6
	1000 mg	1	0	7266	3.9
Sulfonylureas
Glyburide	5 mg	12 754	47.4	14 812	7.9
Gliclazide	60 mg	—	—	95	0.1
Gliclazide	80 mg	4	0	—	—
Glimepiride	2 mg	11	0	962	0.5
Glimepiride	4 mg	26	0.1	469	0.2
DPP-4 Inhibitors^a
Linagliptin	5 mg	—	—	4221	2.2
Linagliptin/Metformin	2.5/500 mg	—	—	401	0.2
	2.5/850 mg	—	—	796	0.4
	2.5/1000 mg	—	—	2200	1.2
Saxagliptin	2.5 mg	—	—	38	0
Saxagliptin	5 mg	—	—	163	0.1
Saxagliptin/Metformin	2.5/1000 mg	—	—	1493	0.8
Saxagliptin/Metformin	5/1000 mg	—	—	442	0.2
Sitagliptin	25 mg	—	—	51	0
	50 mg	4	0	1474	0.8
	100 mg	36	0.1	944	0.5
Sitagliptin/Metformin	50/500 mg	6	0	503	0.3
	50/850 mg	—	—	1781	0.9
	50/1000 mg	3	0	10 272	5.4
	100/1000 mg	—	—	421	0.2
Vildagliptin	50 mg	—	—	925	0.5
Vildagliptin/Metformin	50/500 mg	—	—	339	0.2
	50/850 mg	—	—	1230	0.7
	50/1000 mg	—	—	4902	2.6
GLP-1 agonist^b
Liraglutide	Pen 6 mg/mL/3 mL	—	—	2646	1.4
SGLT-2 Inhibitors^c
Canagliflozin	300 mg	—	—	20	0
Dapagliflozin	10 mg	—	—	979	0.5
Dapagliflozin/Metformin	5/1000 mg	—	—	772	0.4
Dapagliflozin/Metformin	10/1000 mg	—	—	428	0.2
Empagliflozin	10 mg	—	—	652	0.3
Empagliflozin	25 mg	—	—	1344	0.7
Human insulin
Regular	Vial 100 UI/mL/10 mL	2223	8.3	1382	0.7
NPH	Vial 100 UI/mL/10 mL	6191	23.2	5248	2.8
Insulin analogs
Aspartat	Pen 100 UI/mL/3 mL	18	0.1	5798	3.1
Glulisine	Pen 100 UI/mL/3 mL	1	0	16 483	8.8
Glulisine	Vial 100 UI/mL/10 mL	57	0.2	1499	0.8
Lispro	Cartridge 100 UI/mL/3 mL	52	0.2	62	0
Lispro	Vial 100 UI/mL/10 mL	182	0.7	408	0.2
Degludec	Pen 100 UI/mL/3 mL	—	—	5127	2.7
Detemir	Pen 100 UI/mL/3 mL	—	—	4090	2.2
Glargine	Pen 100 UI/mL/3 mL	4	0	35 722	19
Glargine	Vial 100 UI/mL/10 mL	337	1.3	4038	2.1

Dipeptidyl-Peptidase 4 Inhibitor, ^bGlucagon-like peptide-1 receptor agonists, ^cSodium-glucose transport protein 2 Inhibitors.

Table 3.

Prescription of Antidiabetic Drugs by Group and in Combination with Metformin for Patients with Type 2 Diabetes Mellitus in the Last Trimesters of 2008 and 2018.

Antidiabetic drugs		Last quarter 2008		Last quarter 2018
Antidiabetic drugs		n = 26 741	%	n = 188 231	%
Metformin	All	20 545	76.8	159 965	84.9
	Metfomin (monotherapy)	20 545	76.8	134 977	71.7
	Combined	—	—	24 988	13.3
	DPP-4 inhibitor^a	—	—	23 866	12.7
	SGLT-2 Inhibitor^b	—	—	1181	0.6
Other oral antidiabetic drugs	Sulfonylureas	12 790	47.8	16 250	8.6
	DPP-4 Inhibitors	48	0.2	31 308	16.6
	GLP-1 agonist^c	—	—	2646	1.4
	SGLT-2 Inhibitor	—	—	4098	2.2
Insulin	Total	6627	24.8	55 191	29.3
	Regular	2223	8.3	1382	0.7
	NPH	6191	23.2	5248	2.8
	Short acting analog	300	1.1	23 846	12.7
	Long acting analog	340	1.3	47 824	25.4

Dipeptidyl-Peptidase 4 Inhibitor, ^bSodium-glucose transport protein 2 Inhibitors, ^cGlucagon-like peptide-1 receptor agonists.

Use of Aspirin and Statins (Prevention of Cardiovascular Risk)

Among lipid-lowering drugs, the most-prescribed statin in 2008 was lovastatin (98.7% of cases); while atorvastatin was the most-prescribed in 2018 (85.3%) (proportions based on the total number of patients prescribed statins). The drugs used to reduce cardiovascular risk and the prescription frequencies of aspirin and statins are provided in Table 4. Aspirin use decreased from 57.5% in 2008 to 44.2% in 2018, and the use of all statins increased from 44.9% in 2008 to 60.2% in 2018. Notably, the high-intensity statins increased from 1.1% in 2008 to 95.2% in 2018, while the combined use of aspirin + statin continued at about 32% at both times.

Table 4.

Prescription of Drugs for Cardiovascular Prevention in Patients with Type 2 Diabetes Mellitus in the Last Trimesters of 2008 and 2018.

Cardiovascular prevention drugs*		Last quarter 2008		Last quarter 2018
Cardiovascular prevention drugs*		n	%	n	%
Platelet aggregation inhibitors	Pharmaceutical form
Aspirin	100 mg	15 379	57.5	83 280	44.2
Clopidogrel	75 mg	259	1.1	4270	2.3
Clopidogrel/Aspirin	75/100 mg	—	—	4	0.0
Prasugrel	10 mg	—	—	56	0.0
Ticagrelor	90 mg	—	—	300	0.2
Anticholesteremic agents
Atorvastatin	10 mg	7	0.0	2619	1.4
	20 mg	57	0.2	40 669	21.6
	40 mg	53	0.2	53 426	28.4
	80 mg	2	0.0	1457	0.8
Atorvastatin/Ezetimibe	10/10 mg	—	—	13	0.0
	20/10 mg	1	0.0	43	0.0
	40/10 mg	1	0.0	101	0.1
Atorvastatine/Omega 3	80/840 mg capsule	—	—	6	0.0
Lovastatin	20 mg	11 864	44.4	5799	3.1
Pravastatin	20 mg	1	0.0	7	0.0
Pravastatin	40 mg	4	0.0	—	—
Rosuvastatin	10 mg	7	0.0	671	0.4
	20 mg	9	0.0	4626	2.5
	40 mg	—	—	8640	4.6
Rosuvastatin/Ezetimibe	10/10 mg	—	—	22	0.0
	20/10 mg	—	—	123	0.1
	40/10 mg	—	—	399	0.2
Rosuvastatin/Fenofibrate	5/135 mg	—	—	42	0.0
	10/135 mg	—	—	520	0.3
	20/135 mg	—	—	1326	0.7
Simvastatin	10 mg	1	0.0	—	—
	20 mg	—	—	65	0.0
	40 mg	5	0.0	91	0.0
	80 mg	—	—	7	0.0
Simvastatin/Ezetimibe	10/10 mg	1	0.0	10	0.0
	20/10 mg	23	0.1	66	0.0
	40/10 mg	20	0.1	87	0.0
	80/10 mg	—	—	27	0.0
Aspirin and statins prescription
Aspirin	100 mg	15 379	57.5	83 280	44.2
P2Y12 antagonist		259	1.1	4597	2.4
Statin	All	12 010	44.9	11 3315	60.2
	High Intensity^a	132	1.12	107 838	95.22
	Ezetimibe	—	—	870	0.5
Combination therapy	Aspirin+Statin	8569	32.0	61 768	32.8

Total number of patients with high intensity statins/total number of patients with statins.

Tablets, unless otherwise indicated.

Multivariate Analysis

Binary logistic regression revealed statistically significant positive associations of using aspirin and statins in combination in 2008 with male gender (OR: 1.116; 95% CI: 1.056-1.179), age older than 75 years (OR: 6.484; 95% CI: 5.296-7.938) and treatment with clopidogrel (OR: 5.854; 95% CI: 4.463-7.678). In 2018, male patients (OR: 1.262; 95% CI: 1.235-1.289), those older than 75 years of age (OR: 5.819; 95% CI: 5.410-6.258) and those receiving antihypertensive treatment had greater probabilities of receiving prescriptions for aspirin and statins. On the other hand, people receiving fibrates (OR: 0.232; 95% CI: 0.218-0.246) or anticoagulant drugs had a lower probability of receiving the medications for the prevention of cardiovascular risk (see Table 5).

Table 5.

Multivariate Analysis of the Variables Associated with Joint Prescription of Acetylsalicylic Acid and Statins for Patients with Type 2 Diabetes Mellitus in the Last Trimesters of 2008 and 2018.

Multivariate analysis	Last quarter 2008				Last quarter 2018
	P	OR	95% CI^a		P	OR	95% CI
	P	OR	Lower	Upper	P	OR	Lower	Upper
Sex (Male)	<0.001	1.116	1.056	1.179	<.001	1.262	1.235	1.289
Age
18-44 years	Ref	1	Ref	Ref	Ref	1	Ref	Ref
45-59 years	<.001	2.579	2.087	3.186	<.001	3.776	3.514	4.057
60-74 years	<.001	5.113	4.18	6.255	<.001	5.939	5.534	6.373
≥75 years	<.001	6.484	5.296	7.938	<.001	5.819	5.41	6.258
Metformin	<.001	1.56	1.453	1.675	<.001	1.499	1.449	1.55
DPP-4 inhibitors^b	—	—	—	—	<.001	1.123	1.093	1.155
Sulfonylureas	—	—	—	—	<.001	1.226	1.181	1.272
SGLT-2 inhibitors^c	—	—	—	—	<.001	1.429	1.333	1.533
GLP-1 agonist^d	—	—	—	—	<.001	1.378	1.258	1.509
Insulin	<.001	1.809	1.695	1.93	<.001	1.623	1.582	1.666
Clopidogrel	<.001	5.854	4.463	7.678	<.001	2.238	2.086	2.401
NSAID^e	.001	1.132	1.049	1.223	—	—	—	—
Direct oral anticoagulant	—	—	—	—	<.001	0.149	0.133	0.167
Anticholinergics	.078	0.87	0.745	1.016	.02	1.07	1.011	1.133
ARB-II^f	<.001	1.246	1.172	1.326	<.001	2.027	1.975	2.081
β-blockers	—	—	—	—	<.001	2.098	2.046	2.151
β-2 adrenergics	.007	1.226	1.057	1.422	.002	0.91	0.857	0.966
Fibrates	.078	1.069	0.992	1.152	<.001	0.232	0.218	0.246
Heparins	—	—	—	—	<.001	0.789	0.722	0.862
PPI^g	<.001	1.14	1.074	1.21	<.001	1.197	1.169	1.226
ACEI^h	<.001	1.16	1.094	1.23	<.001	2.308	2.235	2.384
Nitrates	—	—	—	—	<.001	2.609	2.287	2.975
Other antihypertensive drug	.086	0.949	0.894	1.008	<.001	1.233	1.205	1.262
Warfarine	—	—	—	—	<.001	0.158	0.133	0.188

An analysis was performed by adjusting associations in 2008 and another in 2018.

Confidence interval, ^bDipeptidyl-Peptidase 4 Inhibitor, ^cSodium-glucose cotransporter-2 inhibitors, ^dGlucagon-like peptide-1 receptor agonists, ^eNonsteroidal anti-inflammatory drugs, ^fAngiotensin II receptor blockers, ^gProton Pump Inhibitor, ^hAngiotensin-converting enzyme inhibitor.

Discussion

General Findings

In 2008 and 2018, one third of patients with T2DM received drugs for the prevention of cardiovascular risk (the combination of aspirin and statins). Between these 2 time points, the proportion of patients receiving antiplatelet prescriptions decreased, whereas there was an increase in prescriptions for lipid-lowering agents. Cardiovascular secondary prevention through the use of aspirin and statins benefits patients by reducing cardiovascular events, and different clinical practice guidelines support the prescription of this combination to reduce morbidity and mortality from cardiovascular-related causes.^8,19

Most T2DM patients in 2008 and 2018 were women, in accordance with previous epidemiological analyses in Colombia,⁷ but men were more likely to receive aspirin or statins, which is consistent with a report by Alfredsson J et al²⁰ where men had a higher probability of being prescribed aspirin (81.0% vs 72.5%) or a statin (82.7% vs 73.0%). Notably, in a number of different age groups, epidemiological studies indicate that the cardiovascular risk of women with T2DM is at least 25% greater than that of men.²¹ This can be explained by differences in the perceived risk of patients and the need for therapy, representing a current gap in pharmacological management, especially in women with T2DM.^22,23 The lower mean age of patients with T2DM in 2018 could indicate an earlier diagnosis from screening programs and better care of noncommunicable chronic diseases such as T2DM, dyslipidemia and HBP.²⁴ In addition, patients older than 75 years were more likely to receive drugs for secondary prevention, possibly due to evidence that age is one of the most important nonmodifiable cardiovascular risk factors. Ramos et al showed that the use of statins reduced atherosclerotic cardiovascular events and mortality from all causes in the population between 75 and 84 years of age; however, in patients older than 85 years, the findings were not significant. In addition, in the PURE study in Latin America, a low prevalence of statin use was found (4% of joint use of cardiovascular prevention drugs), but among those evaluated, patients older than 65 years had a greater probability of receiving them, similar to the present findings.²⁵ This group of patients constitutes a challenge in the clinical setting, and more studies are needed to help focus cardiovascular prevention, especially in those who continue in a good vital state.²⁶

Use of Aspirin and Statins in the T2DM Population

There was also a marked increase in the prescription of high-intensity statins by 2018, which could be related to accumulating evidence on the benefits of these drugs for reducing mortality²⁷ and major cardiovascular events (acute coronary syndrome, cardiac revascularization, and death of cardiovascular origin) compared with statins of moderate or low intensity.²⁸ The increased prescription of high-intensity statins may also be due to their inclusion on the list of medications in the benefit plan of the Colombian health system,²⁹ as well as their recommendation by the clinical practice guidelines of the Ministry of Health of Colombia in 2014. Previously, no such guidelines existed, and there were no specific recommendations for the country.³⁰ However, despite their favorable cardiovascular effects, high-intensity statins are associated with increases of up to 0.4% (P = .0002) in the levels of glycosylated hemoglobin (HbA1c) in patients with T2DM as well as an increased risk of de novo diabetes compared with low-intensity statins.³¹ Therefore, patients risk factors should be reviewed to establish the risk/benefit ratio, and guide the therapy to achieve adequate metabolic control.^32,33

Approximately half of the patients received aspirin; however, only 2% were jointly prescribed clopidogrel, which would indicate that most of the population was receiving aspirin for primary prevention of cardiovascular risk. However, the use of aspirin after the year of presentation of acute coronary syndrome cannot be ruled out, and dual antiplatelet therapy would not be indicated in this case.³⁴ A study in Japan found no evidence that the use of aspirin in low doses for primary prevention in patients with T2DM prevents any cardiovascular event at 10 years, but a significant increase in the risk of gastrointestinal bleeding was observed.^35,36 In addition, although the ASCEND study demonstrated the efficacy of aspirin for the primary prevention of serious vascular events, it also found a 29% higher risk of major bleeding in Caucasian patients³⁷; therefore, the risk/benefit ratio of antiplatelet drugs in primary prevention in patients with high cardiovascular risk, especially those with T2DM, requires further study. The large number of patients receiving aspirin in 2008 could be a medical behavior supported by the recommendations of the 2007 guidelines of the American Heart Association (AHA) and the American Diabetes Association (ADA) for primary prevention in patients with T2DM and high cardiovascular risk.³⁸ However, the clinical practice guideline of the Ministry of Health of Colombia in 2015 advises against the use of aspirin for primary prevention in T2DM patients.³⁹

Diabetes Treatment

With respect to T2DM treatment, the prescription of sulfonylureas decreased markedly in 2018 compared with 2008 (8.6% vs 47.8%). In Colombia, a decrease in the prescription of glyburide has been observed (from 64.9% in 2005 to 21.8% in 2015),^17,18 which is probably related to its association with cardiovascular events, its frequent undesirable effects and the emergence of new antidiabetic drugs such as SGLT-2 inhibitors, GLP-1 receptor agonists and DPP-4 inhibitors. These latter drugs have shown cardiovascular benefits or at least do not increase the risk of cardiovascular events; they are also associated with fewer hypoglycemic events.⁴⁰

The prescription of DPP-4 inhibitors increased significantly between 2008 and 2018 because these drugs are now the second line of treatment according to the recommendations of the clinical practice guidelines for Colombia.⁴ In addition, the proportion of new antidiabetic drugs, such as GLP-1 receptor agonists and SGLT-2 inhibitors, increased. These drugs have a significant impact on major cardiovascular events in high-risk patients^41-43 and are part of the second line of management based on the recommendations of the ADA for patients with T2DM and atherosclerotic cardiovascular disease or chronic kidney disease.⁴⁴ Their use should augment the effect of statins and aspirin on cardiovascular risk in patients who are receiving drugs for primary or secondary prevention because of the potential benefits for reducing cardiovascular events.^45,46

Limitations

This research is limited by the cross-sectional design which compares 2 points in time without analysis of the trends between years. We were unable to access the clinical records of patients; this limited the ability to define the difference between primary and secondary prevention strategies. The findings of this study should be applied to populations with similar insurance characteristics and access to medications. Finally, the strength of this study is the evaluation of the entire population with T2DM affiliated with these insurers to report the changes in national pharmacoepidemiological patterns. The data represents more than 13% of the Colombian population.

Conclusions

With the introduction of national clinical guidelines in Colombia, the management of cardiovascular risk in patients with T2DM seems to be more consistent with international recommendations. The use of aspirin as a prevention measure for cardiovascular risk in patients with T2DM is decreasing, while the use of statins, especially high-intensity statins, has increased over the last decade. The probability of receiving medication for prevention was higher among men, those older than 75 years and patients diagnosed with hypertension. In addition, new antidiabetic drugs that have shown neutral or positive effects on cardiovascular risk are being used more frequently. The changes in drug prescriptions observed in this study suggest that the clinical practice guidelines for the management of patients with T2DM have been adequately implemented. Further research is necessary to understand the findings from this study in relationship to patient and health system outcomes.

Footnotes

Acknowledgements

To Carlos Tovar for his support in the generation of the database.

Author Contributions

Jorge Enrique Machado-Alba participated in Conceptualization, investigation, methodology, project administration, resources, supervision, validation, writing review and editing. Manuel Enrique Machado-Duque participated in data curation, formal analysis, investigation, methodology, validation, writing original and review and editing. Andres Gaviria-Mendoza participated in in formal analysis, methodology, validation, visualization, writing original draft and editing. Diego Arturo Garcia participated in in formal analysis, methodology, validation, visualization, writing original draft and editing. Melissa Hiromi Emura-Vélez participated in in formal analysis, methodology, validation, visualization, writing original draft and editing.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

Statement of Supporting Data

dx.doi.org/10.17504/protocols.io.94yh8xw

ORCID iD

Jorge E. Machado-Alba

References

World Health Organization. About cardiovascular diseases, Cardiovascular disease. 2019. Accessed January 2019. https://www.who.int/cardiovascular_diseases/about_cvd/en/.

Ministerio de Salud y Protección Social. Análisis de Situación de Salud (ASIS) Colombia, 2018. Dirección de Epidemiología y Demografía Bogotá D.C. Colombia 2019. Accessed January 2019. https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/VS/ED/PSP/asis-colombia-2018.pdf.

World Health Organization. Noncommunicable diseases country profiles 2018. Geneva. 2018. Accessed January 2019. https://www.who.int/nmh/publications/ncd-profiles-2018/en/.

Aschner

Munoz

Giron

, et al. Clinical practice guideline for the prevention, early detection, diagnosis, management and follow up of type 2 diabetes mellitus in adults. Colomb Med (Cali). 2016;47:109-131.

Machado-Alba

Machado-Duque

. Cardiovascular risk factors prevalence among patients with dyslipidemia in Colombia. Rev Peru Med Exp Salud Publica. 2013;30(2):205-211.

Hinnen

Kruger

. Cardiovascular risks in type 2 diabetes and the interpretation of cardiovascular outcome trials. Diabetes Metab Syndr Obes. 2019;12:447-455. doi:10.2147/DMSO.S188705

Aschner

. Epidemiología de la diabetes en Colombia. Av Diabetol. 2010;26(2):95-100.

Grundy

Stone

Bailey

, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task force on clinical practice guidelines. J Am Coll Cardiol. 2019;73(24):e285-e350. doi:10.1016/j.jacc.2018.11.003

Newman

Schwartzbard

Weintraub

, et al. Primary prevention of cardiovascular disease in diabetes mellitus. J Am Coll Cardiol. 2017;70(7):883-893.

10.

Jones Freeman

. Strategies for optimizing treatment outcomes. J Manag Care Pharm. 2003;9(1 Suppl):20-23. doi:10.18553/jmcp.2003.9.s1.20

11.

Mindell

Aresu

Zaninotto

, et al. Improving lipid profiles and increasing use of lipid-lowering therapy in England: results from a national cross-sectional survey - 2006. Clin Endocrinol (Oxf). 2011;75(5):621-627.

12.

Primatesta

Poulter

. Lipid concentrations and the use of lipid lowering drugs: evidence from a national cross sectional survey. BMJ. 2000;321(7272):1322-1325.

13.

Cong

Ren

Hou

, et al. Use of cardiovascular drugs for primary and secondary prevention of cardiovascular disease among rural-dwelling older chinese adults. Front Pharmacol. 2020;11:608136.

14.

Ali

Bullard

Saaddine

, et al. Achievement of goals in U.S. diabetes care, 1999-2010. N Engl J Med. 2013;368(17):1613-1624.

15.

Machado-Alba

Murillo-Munoz

Machado-Duque

. Effectiveness of lipid-lowering therapy among a sample of patients in Colombia. Rev Panam Salud Publica. 2013;33(6):383-390.

16.

Machado-Alba

García

Calvo-Torres

, et al. Patrones de prescripción del ácido acetilsalicílico. Rev Colomb Cardiol. 2015;22(3):127-135.

17.

Machado Alba

Moncada Escobar

Mesa Escobar

. Antidiabetic drugs prescription patterns among a group of patients in Colombia. Rev Panam Salud Publica. 2007;22:124-131.

18.

Gaviria-Mendoza

Sánchez-Duque

Medina-Morales

, et al. Prescription patterns and costs of antidiabetic medications in a large group of patients. Prim Care Diabetes. 2018;12:184-191.

19.

Baigent

Blackwell

Collins

, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373:1849-1860.

20.

Alfredsson

Green

Stevens

, et al. Sex differences in management and outcomes of patients with type 2 diabetes and cardiovascular disease: a report from TECOS. Diabetes Obes Metab. 2018;20:2379-2388.

21.

Huebschmann

Huxley

Kohrt

, et al. Sex differences in the burden of type 2 diabetes and cardiovascular risk across the life course. Diabetologia. 2019;62:1761-1772.

22.

de Jong

Vos

de Ritter

, et al. Sex differences in cardiovascular risk management for people with diabetes in primary care: a cross-sectional study. BJGP Open. 2019;3: bjgpopen19X101645.

23.

Wright

Kontopantelis

Emsley

, et al. Cardiovascular risk and risk factor management in type 2 diabetes mellitus. Circulation. 2019;139(24):2742-2753.

24.

Chung

Zhao

Lauderdale

, et al. Initiation of treatment for incident diabetes: evidence from the electronic health records in an ambulatory care setting. Prim Care Diabetes. 2015;9(1):23-30.

25.

Avezum

Oliveira

GBF

Lanas

, et al. Secondary CV prevention in South America in a community setting: the PURE study. Glob Heart. 2017;12:305-313.

26.

Ramos

Comas-Cufi

Marti-Lluch

, et al. Statins for primary prevention of cardiovascular events and mortality in old and very old adults with and without type 2 diabetes: retrospective cohort study. BMJ. 2018;362:k3359.

27.

Rodriguez

Maron

Knowles

, et al. Association between intensity of statin therapy and mortality in patients with atherosclerotic cardiovascular disease. JAMA Cardiol. 2017;2(1):47-54.

28.

Liu

Hao

, et al. Efficacy of high intensity atorvastatin versus moderate intensity atorvastatin for acute coronary syndrome patients with diabetes mellitus. Int J Cardiol. 2016; 222:22-26.

29.

Ministerio de Salud y Protección Social. Resolución Número 5521 de 2013, Colombia. 2013. Accessed January 2019. https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/DE/DIJ/resolucion-5521-de-2013.pdf.

30.

Ministerio de Salud y Protección Social. Guía de Práctica Clínica (GPC) para la prevención, detección temprana, diagnóstico tratamiento y seguimiento de las dislipidemias en la población mayor de 18 años. Guía para profesionales de la salud 2014 - Guía No. 27. Bogotá D.C. 2014. Accessed January 2021. https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/INEC/IETS/GPC-Dislipidemi-completa.pdf

31.

Ooba

Tanaka

Yasukawa

, et al. Effect of high-potency statins on HbA1c in patients with or without diabetes mellitus. J Pharm Health Care Sci. 2016;2:8.

32.

Maki

Diwadkar-Navsariwala

Kramer

. Statin use and risk for type 2 diabetes: what clinicians should know. Postgrad Med. 2018;130(2):166-172.

33.

Zigmont

Shoben

, et al. Statin users have an elevated risk of dysglycemia and new-onset-diabetes. Diabetes Metab Res Rev. 2019;35:e3189.

34.

Bittl

Baber

Bradley

, et al. Duration of dual antiplatelet therapy: a systematic review for the 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Circulation. 2016;134(10):e156-e178.

35.

Ogawa

Nakayama

Morimoto

, et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA. 2008;300(18):2134-2141.

36.

Saito

Okada

Ogawa

, et al. Low-dose aspirin for primary prevention of cardiovascular events in patients with type 2 diabetes mellitus: 10-year follow-up of a randomized controlled trial. Circulation. 2017;135(7):659-670.

37.

Bowman

Mafham

Wallendszus

, et al. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med. 2018;379(16):1529-1539.

38.

Buse

Ginsberg

Bakris

, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care. 2007;30(1):162-172.

39.

Ministerio de Salud y Protección Social. Guía de práctica clínica para el diagnóstico, tratamiento y seguimiento de la diabetes mellitus tipo 2 en la población mayor de 18 años. Sistema General de Seguridad Social en Salud – Colombia. Guía para profesionales de la salud 2015 - Guía No. GPC-2015-5. Bogotá D.C. 2015. Accessed January 2021. http://gpc.minsalud.gov.Co/gpc_sites/Repositorio/Conv_637/GPC_diabetes/DIABETES_TIPO_2_COMPLETA.pdfublica. 2007;22:124-31.

40.

Douros

Dell’Aniello

OHY

, et al. Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study. BMJ. 2018;362:k2693.

41.

Marso

Daniels

Brown-Frandsen

, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311-322.

42.

Neal

Perkovic

Mahaffey

, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644-657.

43.

Zinman

Wanner

Lachin

, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117-2128.

44.

American Diabetes Association. 1. Improving care and promoting health in populations: standards of medical care in diabetes-2018. Diabetes Care. 2018;41:S7-S12.

45.

Anholm

Kumarathurai

Pedersen

, et al. Liraglutide in combination with metformin may improve the atherogenic lipid profile and decrease C-reactive protein level in statin treated obese patients with coronary artery disease and newly diagnosed type 2 diabetes: A randomized trial. Atherosclerosis. 2019;288:60-66.

46.

Giugliano

Maiorino

Bellastella

, et al. Type 2 diabetes and cardiovascular prevention: the dogmas disputed. Endocrine. 2018;60(2):224-228.